The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Researchers evaluated billing for early palliative care among Medicare beneficiaries who were newly diagnosed with 1 of 6 common distant-stage cancers.

NIH officials have urged scientists to remove all references to mRNA vaccine technology from their grant applications.

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Two Harvard medical school professors are suing the Trump administration, arguing that their research was unfairly removed from a government-run website.

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.

Mirvetuximab soravtansine improved overall survival over chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer.